Shirley Ryan AbilityLab is looking for adults with sub-acute spinal cord injuries (SCI) to participate in a trial of experimental drug NVG-291.
For 12 weeks, participants will receive daily subcutaneous injections of either NVG-291 or a placebo. “In lab studies, NVG-291 improved locomotion and bladder recovery,” an AbilityLab announcement said. “Final testing of central nervous system conduction (electrophysiology) as well as upper- and lower-limb function will be assessed after 16 weeks.”
The study is enrolling participants ages 18 to 75, all genders, 10 days to 10 years post cervical spinal cord injury. The study is excluding people whose spinal cord injuries are from gunshot wounds or penetrating injuries; have an implanted device in the brain or spinal cord; or have an implanted pacemaker.
The treatments take place at AbilityLab in Chicago. Contact AbilityLab for more information on enrollment and study details.
Shirley Ryan AbilityLab specializes in spinal cord injury, stroke, brain injury, multiple sclerosis, pediatric and adolescent, and cancer rehabilitation.
